

Progenics Cord Blood Cryobank Annual Quality Report



Company Profile

Progenics Cord Blood Cryobank is a leader in delivering consistent, high quality cord blood processing results, with over 19 years of experience in the cord blood banking industry. Progenics is AABB and FACT Accredited and is registered with both Health Canada and the Food and Drug Administration (FDA) in the United States. The company's mission is to provide the highest quality processing and long-term safe, secure storage of cord blood stem cells, to ensure their availability when needed.

Progenics Cord Blood Cryobank's *modified double stem cell extraction processing technique*, developed by the company's Research and Development Team, ensures that we can guarantee every processed cord blood sample will have a minimum yield of 85% Total Nucleated Cells (TNC).

Contact Us:

Toll Free: 1-866-921-1666

Phone: 416-221-1666

Email: info@progenics.ca

Address: 701 Sheppard Avenue East
Suite 310,
Toronto, ON- M2K 2Z3
Canada

Website: www.progenics.ca

Report Summary

This quality report summarizes the processing results from all the cord blood samples processed by Progenics Cord Blood Cryobank in 2022. The quality indicators referenced in this report present 5 key variables: The Yield (%) of Total Nucleated Cells (TNC), Total Nucleated Cell Viability, CD34+ Viability, Total Nucleated Cell Count, and Viable CD34+ Cell Count.

This report also compares the average monthly and annual percentage yields of TNC including stem cells, the average percentage of total nucleated cell viability, and the average percentage of viable CD34+ cells.

Progenics uses a *modified double stem cell extraction processing technique* which ensures that a higher number of viable nucleated cells are banked for potential medical need. Based on this technique, the average recovery rate for TNCs banked in 2022 has been 94.11%, which is significantly greater than the industry and shows our dedication to maintaining the highest quality standards for each client.

From 2005, 2011, 2012, and 2013, a selection of Cord Blood Units have been tested as part of the Progenics Stability Program to ensure ongoing acceptability of current parameters following cryopreservation. These tests have revealed that the average TNC Viability is 70%, and the CD34+ Viability is 92.78%.

2022 Monthly Report


Month	Total Nucleated Cells (TNC) Yield (%)	Total Nucleated Cell Viability (%)	CD34+ Viability (%)	Total Nucleated Cell Count (x10 ⁶ /unit)	Viable CD34+ Cell Count (x10 ⁶ /unit)
January	95.37	90.68	96.20	900.39	3.29
February	94.87	93.00	96.64	715.42	2.17
March	91.48	89.05	97.13	741.48	3.15
April	91.30	90.42	97.25	768.00	2.83
May	93.22	91.14	96.60	641.95	1.89
June	94.24	89.00	96.72	618.55	1.57
July	95.13	91.89	98.31	773.50	2.58
August	94.71	90.29	98.33	744.97	3.47
September	93.44	89.44	97.69	597.77	1.88
October	95.25	92.91	98.20	730.61	2.50
November	96.18	92.87	98.20	901.75	2.92
December	94.16	92.83	98.69	644.86	1.96
Annual average	94.11	91.13	97.50	731.60	2.52

Notes:

TNC TNC includes all nucleated cells such as stem cells and nucleated red blood cells.

CD34+ Cells Hematopoietic Progenitor Cells

Viability Cell viability is the percentage of viable cells in a processed cord blood sample. The viability of cells is evaluated by either measurement of cell membrane integrity or by measuring certain functions of the cells from a total cell sample.



Conclusion: Comparing Annual Averages

Based on the above data, we confidently report that for 2022, the annual averages are determined for the following parameters:

Post-Processing Parameter	Progenics Annual Average	International FACT Accreditation Standard Requirements
Total Nucleated Cell Yield	94.11%	≥60%
Total Nucleated Cell Viability	91.13%	≥85%
CD34+ Cell Viability	97.50%	n/a
Total Nucleated Cell Count	7.31 x 10 ⁸ /unit	≥5.0 x 10 ⁸ /unit
Viable CD34+ Cell Count	2.52 x 10 ⁶ /unit	≥1.25 x 10 ⁶ /unit

The above results have been made possible due to our *modified double stem cell extraction processing technique* which surpasses our internal quality standards. These results also far exceed FACT International Standard requirements, which are utilized globally for both private and public cord blood banks.



Progenics quality policy assures that processed cord blood units (CBU) will contain a minimum of 85% yield of total nucleated cells (TNC). Once a client's CBU has been processed, and all processing parameters meet our cord blood bank acceptance criteria, the client will receive a *Certificate of Quality* which contains quality indicators of cord blood processing results.

After reviewing the data within this report, we can confidently claim that we offer our clients the highest consistent quality of cord blood processing results.